Form 4: AbCellera Biologics CFO Andrew Booth Reports Share Option Grant

Chief Financial Officer of AbCellera Biologics, Andrew Booth, reports the acquisition of share options.

Summary

• Andrew Booth, the Chief Financial Officer of AbCellera Biologics Inc., filed a Form 4.
• The report details a transaction on January 1, 2025, where Booth acquired share options (right to buy) for 1,352,054 common shares at an exercise price of $2.93.
• These options vest monthly over four years, starting January 1, 2026, contingent upon continuous service to the Issuer.
• Following the reported transaction, Booth beneficially owns 7,942,951 common shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is neither overwhelmingly positive nor negative.

Positives

• The acquisition of share options by a key executive can be seen as a sign of confidence in the company's future performance.

Future Outlook

The vesting of the share options is contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

Share-based compensation is a common practice in the biotechnology industry to align the interests of executives with those of shareholders.

Comparison to Industry Standards

• Share option grants are a typical component of executive compensation packages in the biotech industry, often used by companies like Regeneron, Amgen, and Gilead to incentivize performance and retain key personnel.
• The vesting schedule of four years with monthly installments is a standard practice, similar to what is seen in companies such as Moderna and BioNTech.
• The size of the grant, 1,352,054 shares, should be compared to the total outstanding shares of AbCellera to determine its relative significance, benchmarking against similar grants at peer companies.

Stakeholder Impact

• The share option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates